PI Industries' foray into the pharma industry through two acquisitions will diversify its business and reduce its dependency on agro. The access to CDMO business of pharma will give the company access to global markets in the US, India, and Italy. The deal, valued at 4.2x EV/EBITDA, will be EPS accretive on existing numbers alone and is expected to be 7-8% EPS accretive going forward, with further growth of the two acquired companies contributing to 12-15% EPS growth over the next two years.